Blood and rapid-imaging biomarkers may enable earlier Alzheimer’s monitoring

Observational data associate early plasma p-tau217 decline during lecanemab treatment with better 12-month cognitive outcomes, while accelerated MRI paired with plasma p-tau217 may streamline diagnosis and treatment eligibility. Prospective validation, clinically meaningful thresholds, routine-care performance, and confirmation of treatment-response modifiers such as hypertension remain outstanding; recent commentary emphasizes separating target, pathway, and disease biomarkers.